Discontinued — last reported Q4 '25
CME Group Interest Paid increased by 93.7% to $46.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.7%, from $41.10M to $46.30M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows relatively stable performance with a 0.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $24.70M | $42.30M | $23.90M | $43.40M | $23.90M | $41.40M | $24.50M | $41.10M | $23.90M | $41.00M | $23.90M | $41.10M | $23.90M | $41.00M | $23.90M | $41.10M | $23.90M | $46.70M | $23.90M | $46.30M |
| QoQ Change | — | +71.3% | -43.5% | +81.6% | -44.9% | +73.2% | -40.8% | +67.8% | -41.8% | +71.5% | -41.7% | +72.0% | -41.8% | +71.5% | -41.7% | +72.0% | -41.8% | +95.4% | -48.8% | +93.7% |
| YoY Change | — | — | — | — | -3.2% | -2.1% | +2.5% | -5.3% | +0.0% | -1.0% | -2.4% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +13.9% | +0.0% | +12.7% |